Edition:
United States

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

9.35USD
23 Apr 2018
Change (% chg)

$0.19 (+2.07%)
Prev Close
$9.16
Open
$9.21
Day's High
$9.41
Day's Low
$9.21
Volume
5,428
Avg. Vol
11,512
52-wk High
$15.75
52-wk Low
$5.48

Chart for

About

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein... (more)

Overall

Beta: --
Market Cap(Mil.): $98.89
Shares Outstanding(Mil.): 10.80
Dividend: --
Yield (%): --

Financials

  KALV.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -1.93 -- --
ROI: -49.99 13.60 13.19
ROE: -61.02 15.26 15.00

BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials

* KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001

Jan 05 2018

BRIEF-Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50

* KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS

Dec 14 2017

BRIEF-Ra Capital Management says it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 mln

* Ra Capital Management says ‍​on Oct 12, it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 million - SEC Filing

Nov 13 2017

Earnings vs. Estimates